Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study.
PLoS One. 2017 Jun 5;12(6):e0178463. doi: 10.1371/journal.pone.0178463. eCollection 2017.
Buondonno I1, Rovera G2, Sassi F1, Rigoni MM1, Lomater C2, Parisi S3, Pellerito R2, Isaia GC1, D'Amelio P1.
- Rheumatoid Arthritis nicely treated by Vitamin D (300,000 IU loading dose) – May 2017
- Rheumatoid Arthritis strongly associated with low vitamin D – meta-analysis April 2016
- Rheumatoid arthritis is 40 percent more likely if vitamin D Receptor problem – 2 meta-analyses 2015
- Rheumatoid arthritis reduced by 440,000 IU of Vitamin D over 4 months – Oct 2015
- Overview Rheumatoid Arthritis and vitamin D
- Overview Loading of vitamin D
50,000 weekly for 6-8 weeks is a very popular protocol to restore vitamin D levels
Some doctors prescribe a loading dose of 400,000 in 1 to 7 days
More is needed (or alternate type) if person is obese, has other conditions which lower vitamin D levels such as gallbladder, fatty liver, poor gut, smoke, etc.
The aim of this study was to evaluate differences in T helper cell sub-types and osteoclast (OCs) precursors in peripheral blood between patients affected by early rheumatoid arthritis (eRA) and healthy controls. The effect of administration of cholecalcipherol on clinical and laboratory parameters was subsequently evaluated, by a parallel, randomized double blind, placebo controlled trial.
Thirty nine eRA patients and 31 age-matched controls were enrolled and compared for levels of 25OH vitamin D, T helper cell sub-types, OCs precursors including both classical and non-classical and pro-inflammatory cytokines at baseline. Eligible patients were female ≥18 years of age with a diagnosis of RA, as defined by the American College of Rheumatology 2010 criteria for <6 months prior to inclusion in the study. Patients with auto-immune or inflammatory diseases other than RA were excluded. Patients treated with glucocorticoids (GCs), disease modifying activity drugs and biologic agents within the past 6 months were also excluded. In the second phase of the study, eRA patients were randomly assigned to standard treatment with methotrexate (MTX) and GCs with (21) or without (18) cholecalcipherol (300,000 IU) and followed for 3 months; the randomization was done by computer generated tables to allocate treatments. Three patients didn't come back to the follow up visit for personal reasons. None of the patients experienced adverse events. The main outcome measures were T cells phenotypes, OCs precursors and inflammatory cytokines. Secondary outcome measure were clinical parameters. In eRA, 25OH vitamin D levels were significantly lower. CD4+/IFNγ+,CD4+/IL4+, CD4+/IL17A+ and CD4+IL17A+IFNγ+, cells were increased in eRA as well as non-classical OCs precursors, whereas T regulatory cells were not altered. TNFα, TGFβ1, RANKL, IL-23 and IL-6 were increased in eRA. Non-classical OCs, IL-23 and IL-6 correlated with disease severity and activity. Standard treatment with MTX and GC ameliorated clinical symptoms and reduced IL-23, whereas it did not affect CD4+ cells sub-sets nor OCs precursors.
After 3 months, the combined use of cholecalcipherol significantly ameliorated the effect of treatment on global health. In eRA, a significant imbalance in T CD4+ sub-types accompanied by increased levels of non-classical OCs precursors and pro-inflammatory cytokines was observed. A single dose of cholecalcipherol (300,000 IU) combined with standard treatment significantly ameliorates patients general health.
PMID: 28582403 PMCID: PMC5459341 DOI: 10.1371/journal.pone.0178463